Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bridges

Showing results (361-370 of 403) with videos related to

Pageof 41
Sort By:
Current Topics in Medicinal Chemistry|October 8, 2009
Discovery and development of a potent and highly selective small molecule muscarinic acetylcholine receptor subtype I (mAChR 1 or M1) antagonist in vitro and in vivo probeC David Weaver, Douglas J Sheffler, L Michelle Lewis, et al.
Neuropharmacology|December 1, 2015
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effectsRobert W Gould, Michael T Nedelcovych, Xuewen Gong, et al.
ACS Chemical Neuroscience|November 23, 2012
Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169James C Tarr, Mark L Turlington, Paul R Reid, et al.
Journal of Medicinal Chemistry|September 21, 2013
Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)Mark Turlington, Meredith J Noetzel, Aspen Chun, et al.
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
Molecular Pharmacology|December 3, 2008
Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activityJoy E Marlo, Colleen M Niswender, Emily L Days, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2016
Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in dispositionMichael R Wood, Meredith J Noetzel, James C Tarr, et al.
Public Health in Practice (Oxford, England)|March 2, 2026
Mobilizing community assets to address health equity: Evaluation of the Communities Organizing to Promote Equity (COPE) project in KansasKristina M Bridges, Sharon Fitzgerald Wolff, Sarah Finocchario-Kessler, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
The EMBO Journal|July 29, 2020
Glutamine deprivation alters the origin and function of cancer cell exosomesShih-Jung Fan, Benjamin Kroeger, Pauline P Marie, et al.
Pageof 41

Showing results (361-370 of 403) with videos related to

Sort By:
Pageof 41
Current Topics in Medicinal Chemistry|October 8, 2009
Discovery and development of a potent and highly selective small molecule muscarinic acetylcholine receptor subtype I (mAChR 1 or M1) antagonist in vitro and in vivo probeC David Weaver, Douglas J Sheffler, L Michelle Lewis, et al.
Neuropharmacology|December 1, 2015
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effectsRobert W Gould, Michael T Nedelcovych, Xuewen Gong, et al.
ACS Chemical Neuroscience|November 23, 2012
Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169James C Tarr, Mark L Turlington, Paul R Reid, et al.
Journal of Medicinal Chemistry|September 21, 2013
Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)Mark Turlington, Meredith J Noetzel, Aspen Chun, et al.
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
Molecular Pharmacology|December 3, 2008
Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activityJoy E Marlo, Colleen M Niswender, Emily L Days, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2016
Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in dispositionMichael R Wood, Meredith J Noetzel, James C Tarr, et al.
Public Health in Practice (Oxford, England)|March 2, 2026
Mobilizing community assets to address health equity: Evaluation of the Communities Organizing to Promote Equity (COPE) project in KansasKristina M Bridges, Sharon Fitzgerald Wolff, Sarah Finocchario-Kessler, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
The EMBO Journal|July 29, 2020
Glutamine deprivation alters the origin and function of cancer cell exosomesShih-Jung Fan, Benjamin Kroeger, Pauline P Marie, et al.
Pageof 41